News

The Dose Podcast - Episode 2 "Translating the UNHLM Commitments into Action"


19 Dec 2018
by Working Group

Episode 2: "Translating the UNHLM Commitments into Action: Ensuring Investment in TB R&D to eliminate TB" 

The second episode of The Dose Podcast will focus on the first ever High-Level Meeting on Tuberculosis held by the United Nations General Assembly and the commitments made there to fight TB. The High-Level Meeting is only the fifth time that the UN in its history has called for a high-level meeting devoted to a health issue.  This podcast will highlight the outcomes resulting from the UNHLM, consider how we can hold countries accountable to their commitments, as well as drive the momentum in development of new TB therapies, vaccines and diagnostics.

Moderator: Bobby Ramakant, Citizen News Service

Speaker: Honorable Nick Herbert, Member of Parliament for Arundel and South Downs in the UK.

Speaker: Blessi Kumar, CEO of the Global Coalition of TB Activists

Listen on Soundcloud: https://soundcloud.com/user-87209407/the-does-podcast-episode-2-translating-the-unhlm-commitments-into-action

More News
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...
22 Oct 2020
On Thursday, October 21st, 2020, the U.S. Center for Disease Control and Prevention's (CDC) TB Trials Consortium (TBTC) announced results from their Phase 3, open-label trial: Study 31/A5349. The clinical trial identified a 4-month drug regimen composed of high-dose rifapentine, moxyifloxacin,...
11 Aug 2020
The European Commission (EC) has provided conditional marketing authorization for pretomanid, a novel compound developed by TB Alliance, when used in combination with bedaquiline and linezolid as part of a six month, all-oral regimen for the treatment of adults with XDR-TB or treatment-intolerant...